GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Days Sales Outstanding

VREOF (Vireo Growth) Days Sales Outstanding : 12.74 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Days Sales Outstanding?

Vireo Growth's average Accounts Receivable for the three months ended in Mar. 2025 was $3.43 Mil. Vireo Growth's Revenue for the three months ended in Mar. 2025 was $24.54 Mil. Hence, Vireo Growth's Days Sales Outstanding for the three months ended in Mar. 2025 was 12.74.

The historical rank and industry rank for Vireo Growth's Days Sales Outstanding or its related term are showing as below:

VREOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.72   Med: 7.01   Max: 12.5
Current: 8.5

During the past 13 years, Vireo Growth's highest Days Sales Outstanding was 12.50. The lowest was 5.72. And the median was 7.01.

VREOF's Days Sales Outstanding is ranked better than
98.33% of 959 companies
in the Drug Manufacturers industry
Industry Median: 72.47 vs VREOF: 8.50

Vireo Growth's Days Sales Outstanding increased from Mar. 2024 (7.80) to Mar. 2025 (12.74).


Vireo Growth Days Sales Outstanding Historical Data

The historical data trend for Vireo Growth's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Days Sales Outstanding Chart

Vireo Growth Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.61 5.83 6.54 7.62 9.41

Vireo Growth Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.80 6.92 8.38 10.11 12.74

Competitive Comparison of Vireo Growth's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vireo Growth's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Days Sales Outstanding falls into.


;
;

Vireo Growth Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Vireo Growth's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (2.257 + 2.87) / 2 ) / 99.384*365
=2.5635 / 99.384*365
=9.41

Vireo Growth's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding (Q: Mar. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Mar. 2025 )) / count ) / Revenue (A: Mar. 2025 )*Days in Period
=( (2.87 + 3.983) / 2 ) / 24.541*365 / 4
=3.4265 / 24.541*365 / 4
=12.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vireo Growth  (OTCPK:VREOF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Vireo Growth Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Vireo Growth Business Description

Traded in Other Exchanges
Address
207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs. The company's operating results in one business segment: the cultivation, production, and sale of cannabis.
Executives
Chicago Atlantic Credit Opportunities, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc 10 percent owner 420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen director 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio officer: Chief Operating Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa director, officer: Chief Administrative Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters officer: EVP of Retail C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder officer: General Counsel & CCO 3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller officer: Chief Financial Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402